Cytomx Therapeutics Inc Stock
€3.74
Your prediction
Cytomx Therapeutics Inc Stock
Pros and Cons of Cytomx Therapeutics Inc in the next few years
Pros
Cons
Performance of Cytomx Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytomx Therapeutics Inc | 0.420% | -8.352% | 2.073% | 456.018% | 5.053% | 154.212% | -50.568% |
| Sangamo Therapeutics Inc. | -29.780% | -28.034% | -47.326% | -77.235% | -53.545% | -89.092% | -98.322% |
| Evolus Inc | -0.620% | 13.182% | 16.719% | -56.059% | -17.761% | -42.168% | -41.792% |
| Corbus Pharmaceuticals Holding Inc. | -2.290% | 1.805% | 20.552% | 34.462% | 24.857% | 6696.267% | -79.570% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.CytomX Therapeutics, a player in the biotechnology and medical research sector, presents a mixed bag of financial indicators. On one hand, the market capitalization suggests a relatively modest valuation for its potential; however, the financial statements reveal significant liabilities, negative equity, and consecutive years of net losses, raising some eyebrows about the overall financial health of the company. Diving deeper into the financials showcases the complexities and challenges CytomX faces in navigating the robust landscape of biotechnology.
Research and Development Investment: In the 2023 fiscal year, CytomX allocated $77.68 million toward research and development (R&D). This commitment signals a strong dedication to innovation, crucial for biotech companies that rely on the successful development of new therapies and drugs.
Market Capitalization: With a market capitalization of approximately $98.88 million, CytomX is positioned within a valuation range that reflects cautious optimism from investors. While market size alone doesn’t ensure sustainable growth, it reflects potential that could be unlocked with successful product launches or partnerships.
News
Small Cap or Megacap: Which Healthcare Stock Is Right for You?
When looking for investments in the healthcare space, smaller companies tend to be more alluring. They can be working on drugs or releasing drugs with breakthrough potential. Those companies also
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
CytomX Therapeutics (NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing